Role of a Novel Functional Variant in the PPP2R1A Promoter on the Regulation of PP2A-Aalpha and the Risk of Hepatocellular Carcinoma

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Chen, Hui Feng ^b,c   Mai, Jian Rong ^b   Wan, Jian Xin ^b   Gao, Yan fang ^b   Lin, Li Na ^b   Wang, Song Zi ^b   Chen, Yu Xi ^b   Zhang, Chen Zi ^b   Zhang, Yu Jing ^b   Xia, Bin ^b   Liao, Kun ^b   Lin, Yu Chun ^a,b   Lin, Zhong Ning ^a,b  

^a XIAMEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c Guangdong Prevention and Treatment Center for Occupational Diseases   (China)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHOPROTEIN PHOSPHATASE 2A;

ADULT; AGE; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CHINA; CONTROLLED STUDY; CPG ISLAND; ENZYME ACTIVE SITE; ENZYME REGULATION; FEMALE; GENETIC POLYMORPHISM; GENETIC REGULATION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS B VIRUS; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METHYLATION; PPP2R1A GENE; PROMOTER REGION; RISK REDUCTION; SEX DIFFERENCE; TRANSCRIPTION REGULATION;

ADULT; CARCINOMA, HEPATOCELLULAR; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIVER NEOPLASMS; MALE; NF-KAPPA B; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PROTEIN PHOSPHATASE 2; TRANSCRIPTION, GENETIC; TUMOR MARKERS, BIOLOGICAL;

HEPATITIS B VIRUS;

EID: 84875499090     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059574     Document Type: Article

References (61)

1. Moorhead GB, Trinkle-Mulcahy L, Ulke-Lemee A, (2007) Emerging roles of nuclear protein phosphatases. Nat Rev Mol Cell Biol 8: 234-244.
2. Chen W, Possemato R, Campbell KT, Plattner CA, Pallas DC, et al. (2004) Identification of specific PP2A complexes involved in human cell transformation. Cancer Cell 5: 127-136.
3. Sablina AA, Hector M, Colpaert N, Hahn WC, (2010) Identification of PP2A complexes and pathways involved in cell transformation. Cancer Res 70: 10474-10484.
4. Hemmings BA, Adams-Pearson C, Maurer F, Muller P, Goris J, et al. (1990) alpha- and beta-forms of the 65-kDa subunit of protein phosphatase 2A have a similar 39 amino acid repeating structure. Biochemistry 29: 3166-3173.
5. Hendrix P, Mayer-Jackel RE, Cron P, Goris J, Hofsteenge J, et al. (1993) Structure and expression of a 72-kDa regulatory subunit of protein phosphatase 2A. Evidence for different size forms produced by alternative splicing. J Biol Chem 268: 15267-15276.
6. Calin GA, di Iasio MG, Caprini E, Vorechovsky I, Natali PG, et al. (2000) Low frequency of alterations of the alpha (PPP2R1A) and beta (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms. Oncogene 19: 1191-1195.
7. Lin YC, Chen HF, Lin LN, Luo J, Li W, et al. (2011) Identification and functional analyses of polymorphism haplotypes of protein phosphatase 2A-Aalpha gene promoter. Mutat Res 716: 66-75.
8. Robertson KD, (2005) DNA methylation and human disease. Nat Rev Genet 6: 597-610.
9. Yoo CB, Jones PA, (2006) Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5: 37-50.
10. Farazi PA, DePinho RA, (2006) Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6: 674-687.
11. El-Serag HB, Rudolph KL, (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576.
12. Sunahori K, Juang YT, Tsokos GC, (2009) Methylation status of CpG islands flanking a cAMP response element motif on the protein phosphatase 2Ac alpha promoter determines CREB binding and activity. J Immunol 182: 1500-1508.
13. Su H, Yang JR, Xu T, Huang J, Xu L, et al. (2009) MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res 69: 1135-1142.
14. Lin Z, Zhang X, Tuo J, Guo Y, Green B, et al. (2008) A variant of the Cockayne syndrome B gene ERCC6 confers risk of lung cancer. Hum Mutat 29: 113-122.
15. Zhang S, Lin ZN, Yang CF, Shi X, Ong CN, et al. (2004) Suppressed NF-kappaB and sustained JNK activation contribute to the sensitization effect of parthenolide to TNF-alpha-induced apoptosis in human cancer cells. Carcinogenesis 25: 2191-2199.
16. Chen HF, Lin LN, Chen YX, Wan JX, Luo J, et al. (2012) Identification and functional analysis of variant haplotypes in the 5'-flanking region of protein phosphatase 2A-Bdelta gene. PLoS One 7: e35524.
17. Xiong XD, Fang JH, Qiu FE, Zhao J, Cheng J, et al. (2008) A novel functional polymorphism in the Cdc6 promoter is associated with the risk for hepatocellular carcinoma. Mutat Res 643: 70-74.
18. Schutte K, Bornschein J, Malfertheiner P, (2009) Hepatocellular carcinoma-epidemiological trends and risk factors. Dig Dis 27: 80-92.
19. Livak KJ, (1999) Allelic discrimination using fluorogenic probes and the 5' nuclease assay. Genet Anal 14: 143-149.
20. Dupont WD, Plummer WD Jr, (1990) Power and sample size calculations. A review and computer program. Control Clin Trials 11: 116-128.
21. Brookes AJ, (1999) The essence of SNPs. Gene 234: 177-186.
22. Hudson TJ, (2003) Wanted: regulatory SNPs. Nat Genet 33: 439-440.
23. Stepanova M, Tiazhelova T, Skoblov M, Baranova A, (2006) Potential regulatory SNPs in promoters of human genes: a systematic approach. Mol Cell Probes 20: 348-358.
24. Sun T, Gao Y, Tan W, Ma S, Shi Y, et al. (2007) A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. Nat Genet 39: 605-613.
25. Park JY, Park JM, Jang JS, Choi JE, Kim KM, et al. (2006) Caspase 9 promoter polymorphisms and risk of primary lung cancer. Hum Mol Genet 15: 1963-1971.
26. Ezzikouri S, El Feydi AE, Benazzouz M, Afifi R, El Kihal L, et al. (2009) Single nucleotide polymorphism in DNMT3B promoter and its association with hepatocellular carcinoma in a Moroccan population. Infect Genet Evol 9: 877-881.
27. Millward TA, Zolnierowicz S, Hemmings BA, (1999) Regulation of protein kinase cascades by protein phosphatase 2A. Trends Biochem Sci 24: 186-191.
28. Sablina AA, Chen W, Arroyo JD, Corral L, Hector M, et al. (2007) The tumor suppressor PP2A Abeta regulates the RalA GTPase. Cell 129: 969-982.
29. Esplin ED, Ramos P, Martinez B, Tomlinson GE, Mumby MC, et al. (2006) The glycine 90 to aspartate alteration in the Abeta subunit of PP2A (PPP2R1B) associates with breast cancer and causes a deficit in protein function. Genes Chromosomes Cancer 45: 182-190.
30. Takagi Y, Futamura M, Yamaguchi K, Aoki S, Takahashi T, et al. (2000) Alterations of the PPP2R1B gene located at 11q23 in human colorectal cancers. Gut 47: 268-271.
31. Wang SS, Esplin ED, Li JL, Huang L, Gazdar A, et al. (1998) Alterations of the PPP2R1B gene in human lung and colon cancer. Science 282: 284-287.
32. Chen W, Arroyo JD, Timmons JC, Possemato R, Hahn WC, (2005) Cancer-associated PP2A Aalpha subunits induce functional haploinsufficiency and tumorigenicity. Cancer Res 65: 8183-8192.
33. Suzuki K, Takahashi K, (2006) Induction of E-cadherin endocytosis by loss of protein phosphatase 2A expression in human breast cancers. Biochem Biophys Res Commun 349: 255-260.
34. Chen HG, Han WJ, Deng M, Qin J, Yuan D, et al. (2009) Transcriptional regulation of PP2A-A alpha is mediated by multiple factors including AP-2alpha, CREB, ETS-1, and SP-1. PLoS One 4: e7019.
35. Esteller M, (2008) Epigenetics in cancer. N Engl J Med 358: 1148-1159.
36. Bird A, (2002) DNA methylation patterns and epigenetic memory. Genes Dev 16: 6-21.
37. Wilson AS, Power BE, Molloy PL, (2007) DNA hypomethylation and human diseases. Biochim Biophys Acta 1775: 138-162.
38. Keen JC, Garrett-Mayer E, Pettit C, Mack KM, Manning J, et al. (2004) Epigenetic regulation of protein phosphatase 2A (PP2A), lymphotactin (XCL1) and estrogen receptor alpha (ER) expression in human breast cancer cells. Cancer Biol Ther 3: 1304-1312.
39. Keen JC, Zhou Q, Park BH, Pettit C, Mack KM, et al. (2005) Protein phosphatase 2A regulates estrogen receptor alpha (ER) expression through modulation of ER mRNA stability. J Biol Chem 280: 29519-29524.
40. Ogino S, Hazra A, Tranah GJ, Kirkner GJ, Kawasaki T, et al. (2007) MGMT germline polymorphism is associated with somatic MGMT promoter methylation and gene silencing in colorectal cancer. Carcinogenesis 28: 1985-1990.
41. Chen H, Taylor NP, Sotamaa KM, Mutch DG, Powell MA, et al. (2007) Evidence for heritable predisposition to epigenetic silencing of MLH1. Int J Cancer 120: 1684-1688.
42. Kloth M, Goering W, Ribarska T, Arsov C, Sorensen KD, et al. (2012) The SNP rs6441224 influences transcriptional activity and prognostically relevant hypermethylation of RARRES1 in prostate cancer. Int J Cancer 131: E897-904.
43. Boumber YA, Kondo Y, Chen X, Shen L, Guo Y, et al. (2008) An Sp1/Sp3 binding polymorphism confers methylation protection. PLoS Genet 4: e1000162.
44. Dupont WD, Breyer JP, Bradley KM, Schuyler PA, Plummer WD, et al. (2010) Protein phosphatase 2A subunit gene haplotypes and proliferative breast disease modify breast cancer risk. Cancer 116: 8-19.
45. Janssens V, Goris J, Van Hoof C, (2005) PP2A: the expected tumor suppressor. Curr Opin Genet Dev 15: 34-41.
46. Huang W, Batra S, Atkins BA, Mishra V, Mehta KD, (2005) Increases in intracellular calcium dephosphorylate histone H3 at serine 10 in human hepatoma cells: potential role of protein phosphatase 2A-protein kinase CbetaII complex. J Cell Physiol 205: 37-46.
47. Dung TD, Chang HC, Binh TV, Lee MR, Tsai CH, et al. (2012) Zanthoxylum avicennae extracts inhibit cell proliferation through protein phosphatase 2A activation in HA22T human hepatocellular carcinoma cells in vitro and in vivo. Int J Mol Med 29: 1045-1052.
48. Chen KF, Yu HC, Liu TH, Lee SS, Chen PJ, et al. (2010) Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. J Hepatol 52: 88-95.
49. Duong FH, Christen V, Lin S, Heim MH, (2010) Hepatitis C virus-induced up-regulation of protein phosphatase 2A inhibits histone modification and DNA damage repair. Hepatology 51: 741-751.
50. Arsura M, Cavin LG, (2005) Nuclear factor-kappaB and liver carcinogenesis. Cancer Lett 229: 157-169.
51. Sakurai T, Maeda S, Chang L, Karin M, (2006) Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc Natl Acad Sci U S A 103: 10544-10551.
52. Luedde T, Beraza N, Kotsikoris V, van Loo G, Nenci A, et al. (2007) Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 11: 119-132.
53. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, et al. (2004) NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431: 461-466.
54. Yu MW, Yang YC, Yang SY, Cheng SW, Liaw YF, et al. (2001) Hormonal markers and hepatitis B virus-related hepatocellular carcinoma risk: a nested case-control study among men. J Natl Cancer Inst 93: 1644-1651.
55. Kane MA, (2003) Global control of primary hepatocellular carcinoma with hepatitis B vaccine: the contributions of research in Taiwan. Cancer Epidemiol Biomarkers Prev 12: 2-3.
56. Tarn C, Lee S, Hu Y, Ashendel C, Andrisani OM, (2001) Hepatitis B virus X protein differentially activates RAS-RAF-MAPK and JNK pathways in X-transforming versus non-transforming AML12 hepatocytes. J Biol Chem 276: 34671-34680.
57. Nijhara R, Jana SS, Goswami SK, Rana A, Majumdar SS, et al. (2001) Sustained activation of mitogen-activated protein kinases and activator protein 1 by the hepatitis B virus X protein in mouse hepatocytes in vivo. J Virol 75: 10348-10358.
58. Nijhara R, Jana SS, Goswami SK, Kumar V, Sarkar DP, (2001) An internal segment (residues 58-119) of the hepatitis B virus X protein is sufficient to activate MAP kinase pathways in mouse liver. FEBS Lett 504: 59-64.
59. Feitelson MA, Sun B, Satiroglu Tufan NL, Liu J, Pan J, et al. (2002) Genetic mechanisms of hepatocarcinogenesis. Oncogene 21: 2593-2604.
60. Tang G, Minemoto Y, Dibling B, Purcell NH, Li Z, et al. (2001) Inhibition of JNK activation through NF-kappaB target genes. Nature 414: 313-317.
61. De Smaele E, Zazzeroni F, Papa S, Nguyen DU, Jin R, et al. (2001) Induction of gadd45beta by NF-kappaB downregulates pro-apoptotic JNK signalling. Nature 414: 308-313.